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Thyroid cancers have been the main medical consequence of the Chernobyl accident. On the basis of their pathological features and
of the fact that a large proportion of them demonstrate RET-PTC translocations, these cancers are considered as similar to classical
sporadic papillary carcinomas, although molecular alterations differ between both tumours. We analysed gene expression in post-
Chernobyl cancers, sporadic papillary carcinomas and compared to autonomous adenomas used as controls. Unsupervised clustering
of these data did not distinguish between the cancers, but separates both cancers from adenomas. No gene signature separating
sporadic from post-Chernobyl PTC (chPTC) could be found using supervised and unsupervised classification methods although such
a signature is demonstrated for cancers and adenomas. Furthermore, we demonstrate that pooled RNA from sporadic and chPTC
are as strongly correlated as two independent sporadic PTC pools, one from Europe, one from the US involving patients not
exposed to Chernobyl radiations. This result relies on cDNA and Affymetrix microarrays. Thus, platform-specific artifacts are
controlled for. Our findings suggest the absence of a radiation fingerprint in the chPTC and support the concept that post-Chernobyl
cancer data, for which the cancer-causing event and its date are known, are a unique source of information to study naturally
occurring papillary carcinomas.
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Thyroid cancer is the most common form of solid neoplasm
associated with radiation exposure. There has been a considerable
increase in thyroid cancer after the Chernobyl nuclear power plant
accident, particularly in subjects who were in childhood or
adolescence at the time of exposure. This is due to the exposure
of the population to I
131 and shorter lived radioisotopes of iodine.
These thyroid cancers have been identified as papillary carcinomas
on the basis of their pathology (Robbins and Schneider, 1998;
Shibata et al, 2001). Thyroid cancers related to external radiation
in the US have been diagnosed as papillary carcinomas on the
same basis (Roudebush et al, 1978). As the incidence of thyroid
cancer in young children and adolescents is very low in unexposed
populations, the majority of thyroid cancers occurring in this
population can be ascribed to a direct result of exposure to
radiation (Malone et al, 1991). The Chernobyl accident therefore
provides a unique opportunity to characterize radiation-induced
thyroid cancer.
RET proto-oncogene rearrangements (frequency: B30% in
adult PTC) and BRAF somatic mutations (frequency: 36–69% in
adult PTC) (Cohen et al, 2003; Kimura et al, 2003; Soares et al,
2003) represent the most common genetic alterations found in
sporadic, naturally occurring, papillary thyroid carcinomas (PTC).
RET rearrangements result from the fusion of the RET tyrosine
kinase domain with the N-terminus part of different proteins,
creating chimeric oncogenes with constitutive activity, named
RET/PTC (Jhiang, 2000). At least 15 different RET/PTC variants
have been described so far involving rearrangement with 10
different genes (Tallini and Asa, 2001).
Post-Chernobyl PTC (chPTC) have shown so far a higher
frequency of rearrangement of the RET/PTC oncogene (Nikiforov
et al, 1997) and lower frequency of BRAF mutation (Nikiforova
et al, 2004) than is observed in adult PTC. This may be linked to
the particular effectiveness of radiation in causing double-strand
breaks and gene rearrangements, rather than point mutations. RET
rearrangements, which would be the direct results of double-strand
breaks repairs and which are thus presumed to be early events in
thyroid tumorigenesis, are found in about 60% of these tumours
(Fugazzola et al, 1995; Klugbauer et al, 1995; Bounacer et al, 1997).
The majority of these are RET/PTC3 rearrangements and are
associated with a solid/follicular subtype of PTC, while the less
frequent RET/PTC1 rearrangement is associated with the classic
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sand diffuse sclerosing variants (Thomas et al, 1999; Santoro et al,
2000). While the presence of RET/PTC translocations in a sizeable
proportion of post-Chernobyl thyroid cancers and sporadic
papillary carcinomas is an argument in favour of the identity of
both types of tumours, the different proportions of the types of
translocation could suggest a different molecular phenotype.
Gene expression profiling of clinical samples by microarray
offers unprecedented opportunities to define molecular signatures
of the pathology of tissue samples. In this work, we show that,
while hyperfunctioning thyroid adenomas and papillary carcino-
mas are easily distinguishable on the basis of their gene expression
patterns, post-Chernobyl, radiation-induced PTC have the same
molecular phenotype as sporadic PTC (sPTC) from Belgium,
France and the US. This suggests that a molecular signature for
radiation-induced thyroid cancer is very unprobable.
MATERIALS AND METHODS
Tissue samples
Human thyroid samples were obtained after surgical resection for
thyroid tumours: 8 sPTC, 12 chPTC, and 13 autonomously
functioning adenomas. The tissues were immediately kept at 41C,
dissected, snap-frozen in liquid nitrogen and then stored at  801C
till processing. The protocol received approval from the ethics
committees of the institutions.
RNA purification
The frozen tissues were reduced to powder in liquid nitrogen, and
total RNA was extracted using a Trizol reagent kit (Life
Technologies Inc., CA, USA) followed by purification on Qiagen
RNeasy columns. The concentration of the RNA was assessed
spectrophotometrically and its integrity was verified by visualisa-
tion of intact 18S and 28S ribosomal RNA bands after gel
migration. Samples from post-Chernobyl thyroid cancers were
obtained via the Chernobyl Tissue Bank (http://www.chernobyl-
tissuebank.com).
The presence of RET/PTC gene rearrangement was analysed by
RT–PCR as described by Santoro et al (2000), and the presence of
mutated BRAF
T1796A was detected as described by Nikiforova et al
(2003).
Micromax cDNA microarray hybridisation
Tumour RNA extracts were hybridised together with patient-
matched nontumoral thyroid tissues on Micromax Human cDNA
microarray system (Perkin-Elmer, Wellesley, MA, USA), contain-
ing 2400 known human cDNA, mapping to B2100 UniGene (build
160) clusters. All hybridisations were replicated with fluorescent
dyes swapped between tumour/nontumoral pairs. Total RNA (1–
1.5mg/slide) was labelled with fluorescein or biotin according to
the manufacturer’s instructions (Micromax labelling kit, Perkin-
Elmer Life Science). After resin column purification (Microcon
YM-100, Millipore, Billerica, MA, USA) and ethanol precipitation,
each labelled target was resuspended in 30ml hybridisation buffer
containing 50% formamide, 7  SSPE (20  SSPE¼3.6 M NaCl,
0.2 M sodium phosphate, pH 8.3, 20mM EDTA), 5  Denhardt’s
(0.1% Ficoll, 0.1% polyvinylpyrrolidone), 0.5% SDS, along with
10mg of polydA (Research Genetics, Groningen, The Netherlands)
and 10mg of Cot-1 DNA (Gibco Life Sciences, Paisley, UK), which
were added in order to reduce cross-hybridisation and nonspecific
hybridisation. The arrays were prehybridised at 421 for 30min in
5  Denhardt, 7  SSPE, 0.5% SDS and 1% bovine serum albumin.
Prior to hybridisation, carried out overnight at 421C in a Corning
hybridisation chamber, the labelled cDNA was denatured for 3min
at 951C and then incubated at 421C for 20min. Following the
hybridisation, the arrays were washed twice with 0.1  SSC (1 
SSC¼0.15 M NaCl, 0.015 M sodium citrate), 0.1% SDS for 10min
and three times with 0.1  SSC for 10min. Fluorescein and biotin
labelled cDNAs were sequentially detected according to the
tyramide signal amplification (TSA) process, following the
manufacturer’s instructions: hybridisation signal from fluorescein
labelled cDNA was amplified with antifluorescein antibody
coupled to horseradish peroxidase (HRP) and cyanine 3 tyramide,
while hybridisation signal from biotin labelled cDNA was
amplified with streptavidin, HRP-coupled, and cyanine 5 tyramide.
Preprocessing of microarray data
Micromax arrays were scanned on a GMS 418 array scanner
(Affymetrix, Santa Clara, CA, USA). Scans were quantified at
multiple gains with ImaGene 4.0 (Biodiscovery, Marina del Rey,
CA, USA). Each experiment was performed at least twice with dye
swap. Quantification performed at different gains were merged in
order to better capture the full dynamic range of fluorescence
intensities. The scan merging algorithm is implemented in the
MatArray toolbox (Venet, 2003). Following background substrac-
tion, the resulting expression measurements were corrected for
spatial and intensity biases using algorithms from the MatArray
toolbox (Venet, 2003). Corrected log-ratios of on-slide and dye-
swap replicates were averaged. cDNA probes mapping to the same
LocusLink ID were also averaged.
Unsupervised classification
Hierarchical clustering was performed on the basis of the 50%
genes with the highest median intensity, using the Pearson
correlation distance and Ward linkage as implemented in the
mva library of the R 1.9.0 statistical package (R development Core
Team, 2004). Multidimensional scaling was performed on all genes.
We used the Pearson correlation distance, and the isoMDS
function from the MASS library (Venables and Ripley, 2002) for
R. The R 1.9.0 implementation of k-mean was used. The algorithm
was run 100 times with random initial conditions, and with two
centres, on the full data set. Classification results were then derived
by majority voting over the 100 runs. The same procedure was
repeated on PTC alone to search for a sporadic/post-Chernobyl
separation.
Detection of differentially expressed genes
Differentially expressed genes were searched for with the
significance analysis of microarray (SAM) procedure (Tusher
et al, 2001) as implemented in the siggenes library (Schwender,
2003) for R. This permutation-based method avoids parametric
hypotheses and handles multiple testing issues inherent to
microarray data. A total of 1000 random permutations or the
class labels were examined in each run of SAM.
Supervised classification
Expression signatures separating tumour types were found with an
algorithm akin to diagonal linear discriminants introduced by
Golub et al (1999), and discussed by Dudoit et al (2002).
Discriminating signatures were assessed by cross-validation.
Two-third of the samples were selected randomly and used to
build the signature. The remaining 1/3 samples were used to test its
classification performances. Classification errors were averaged
over 100 runs of this protocol. In order to compute an upper
bound for the P-values of the classification error, the entire cross-
validation procedure was repeated 100 times on the data with
randomly permuted class labels. In order to check that the three-
fold cross-validation scheme was not too stringent to obtain result
for the sporadic/post-Chernobyl cancer classification, we also run
leave-one-out cross-validation for this task. Again, sporadic and
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spost-Chernobyl cancers could not be separated. Supervised
classification was also performed using the Pelora algorithm
(Dettling and Bu ¨hlmann, 2004) as implemented in the supclust
library for R, with parameters l¼1/16 and n¼10 groups, and the
cross-validation protocol with 2/3–1/3 training-testing split
described above.
Correlation analysis
Tumour RNA extracts from 14 sPTC were pooled and hybridised
with their respective control pools on dual channel Human 5k
microarrays (Flanders Interuniversity Institute for Biotechnology,
Leuven, Belgium, http://www.microarrays.be). The Human 5k slide
set includes four slides onto which 18442 ESTs representing 13000
human genes are spotted in duplicate. A dye-swap hybridisation
was performed. A similar protocol was applied to RNA extracts
from 13 chPTC and from five autonomously functioning adenoma.
The chPTC pool, however, was hybridised on Human 21k
microarrays (Flanders Interuniversity Institute for Biotechnology,
Leuven, Belgium), which include 21000 ESTs representing 16000
genes. All microarrays were processed according to Flanders
Interuniversity Institute for Biotechnology’s standard protocol
(http://www.microarray.be/service.htm). Background-corrected,
intensity-normalised, data were used in subsequent analysis.
We downloaded the raw Affymetrix HGU95 data (CEL files,
http://thinker.med.ohio-state.edu/ptc/) of Huang et al (2001) and
normalised them with the RMA method (Irizarry et al, 2003) as
implemented in the ‘rma’ function of the Bioconductor package
(version 1.4, http://www.bioconductor.org/) for the R statistical
language. Log-ratios were computed and averaged over all eight
patients of Huang’s study. For each data set, further averaging was
performed over probe sets mapping to a same UniGene cluster.
Pearson correlations between averaged log-ratios were then
computed over the 6425 UniGene clusters represented on the
HGU95, Human 5k, and Human 21k platforms. Pearson correla-
tions were then computed on the resulting log-ratios.
Real-time RT–PCR
5mg of total RNA was treated with 5U DNAseI (Life Technologies)
during 15min at room temperature in a total volume of 50mli n
order to remove possible genomic DNA contamination. The whole
reaction volume was then subjected to reverse transcription using
Superscript II (Life Technologies) as described by the manufac-
turer, in a final volume of 100ml (0.05mg cDNA/100ml), and the
cDNA obtained was diluted five times. Oligonucleotide sequences
(primers and probes) corresponding to the selected transcripts
were designed using Primer Express software (Applied Biosystems,
CA, USA). The nucleotide sequence of the primers and the probes
are available upon request. The Taqman probes carry a 50 reporter
label (FAM) and a 30 dark quencher (Dabcyl). Relative quantifica-
tions of gene expression were performed with the ABI Prism 7700
Sequence Detection System (AB/Perkin-Elmer) using 2ml of the
diluted cDNA product as template for each reaction, 300nM of a
forward and a reverse primer, 100nM probe and the quantitative
PCR mastermix with ROX as the passive reference (Eurogentec,
Lie `ge, Belgium) in a total volume of 30ml. The mastermix contains
a hotstart enzyme, which is activated by heating for 10min at 951C.
Amplification was carried out using 40 PCR cycles consisting of a
two-step procedure, 60s at 601C and 60s at 951C. The threshold
cycle (Ct) was determined as the fractional cycle number at which
the amount of amplified target reached a threshold, which was
fixed at 0.06, where all the amplification curves were above
background fluorescence and still in exponential phase. For
calculating the expression level, we used a mathematical model
developed by Pfaffl (2001), which determines the relative
quantification of a target gene in comparison to a reference gene
(PBGD) based on the PCR efficiencies of each gene and the Ct






DCPpbgdðcontrol sampleÞ with E ¼ 10ð 1=slopeÞ
All the real-time RT–PCR experiments were performed in
duplicate or triplicate.
RESULTS
Different clustering algorithms do not separate sporadic
and chPTC, but do separate autonomous adenomas (AAs)
from PTC
Microarray experiments were performed using the Micromax
cDNA system from Perkin-Elmer, containing 2400 known human
cDNA spotted in duplicate. For each sample, experiments were
duplicated with dye swap, and the averages of the intensity ratios
(tumour/control) resulting from each dye combination were
calculated (see Materials and Methods). In total, 20 cases of PTC
were studied: among the latter, eight were cases with no history of
radiation exposure, treated surgically at the Erasmus Hospital
(Free University of Brussels, Belgium), or at the A Pare ´ Hospital
(AP-HP, Boulogne, France), and 12 samples were chPTC obtained
from the Chernobyl Tissue Bank. The clinical parameters and gene
alterations, including BRAF
T1796A mutation and RET/PTC gene
rearrangements, for each of the cases examined in this study are
summarised in Table 1. In addition, 13 autonomous thyroid
adenomas (AA) were included as controls, that is, to demonstrate
that the methods applied in the paper do detect differences
between differing tumour types. Hierarchical clustering of the
samples, performed using the 50% most expressed genes,
separated papillary carcinomas from AAs except for two samples,
p2 and ch123 (Figure 1). However, no such separation was
observed between the PTC of different aetiology: there was no
clustering of the sPTC separately from chPTC. In addition, chPTC
could not be segregated into those which harboured a RET/PTC
rearrangement and those that did not. Similar results were
obtained using k-mean classification (not shown, see Materials
and Methods), and were further confirmed with multidimensional
scaling on the basis of all 2400 genes, as shown in Figure 2.
Multidimensional scaling (Venables and Ripley, 2002) collapses
the 2400 dimensions gene expression data into two dimensions
while preserving the distance relationship between samples. Its
strength over hierarchical clustering is that it is a continuous
representation of the data faithful to the continuous nature of the
gene expression space. Adenomas are tightly grouped in the two-
dimensional embedding, and well separated from the PTC.
Sporadic and chPTC are mixed up. Samples ch123 and p2, which
were misclassified by hierarchical clustering and by k-mean are
apart from the PTC group, and from the adenomas group. The
strikingly different patterns of gene expression in AAs and
papillary carcinomas are entirely consistent with the known
mutually exclusive genotypes, which often cause these lesions:
constitutive activation of the thyrotropin (TSH)/cAMP and of the
RET/PTC–RAS–RAF–MAP kinase pathways respectively.
Several of our microarray results are in accordance with
previous data obtained in our group by Northern blot analysis
(Deleu et al, 2000), or with data from the litterature (Huang et al,
2001; Wasenius et al, 2003; Eszlinger et al, 2004; Finley et al,
2004a,b). In addition, we validated our microarray data by
evaluating the expression of selected transcripts using real-time
RT–PCR (Figure 3).
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sSAM analysis cannot differentiate sporadic from chPTC,
but finds genes differing between adenomas and PTC
Significance analysis of microarray (SAM) (Tusher et al, 2001) is a
procedure that detects differentially expressed genes without
making hypotheses on the distribution of expression levels, and
with a rigorous handling of the fact that thousands of hypotheses
are being tested at once in a microarray analysis. As a statistically
Table 1 Summary of the clinical parameters and gene alterations of the post-Chernobyl and sporadic papillary thyroid carcinomas studied
Sample name Age Sex Tumour size (cm) Histological variant of PTC Genotype Regional LN metastasis Distant metastasis
Post-Chernobyl
ch155 12 F 2.5 Solid RET/PTC3 +  
ch104 12 M 4.5 Papillary RET/PTC3 +  
ch163 11 M 4.5 Follicular neg +  
ch12 14 F 2 Solid RET/PTC3 + +
ch70 18 F 5.5 Papillary neg + +
ch109 13 F 7 Papillary RET/PTC1 +  
ch123 13 F 5 Follicular neg + +
chs405 16 F 3 Papillary RET/PTC +  
ch414 33 F 2.5 Follicular neg   
chs420 28 F 1.4 Follicular neg   
chs422 31 M 0.9 Follicular BRAF
T1796A + (few cells)  
chs423 22 F 4.5 Papillary neg   
Sporadic:
p1 51 M 2.5 Follicular RET/PTC +  
p2 49 M 0.4 Papillary ND   
p3 59 M 6 Papillary neg +  
p4 62 M 1 Papillary BRAF
T1796A NA NA
p5 45 F 3 Follicular BRAF
T1796A   
p6 37 M 5 Papillary ND +  
p11 37 F 1.5 Papillary neg +  
p14 32 M 1.9 Follicular RET/PTC   
















































































































Figure 1 Hierarchical clustering of the microarray data from 13
autonomous adenomas (noted a or v) and 20 PTC (p: sporadic, ch:
post-Chernobyl PTC). The colour bar below the dendogram depicts
tumour types: green, autonomous adenomas; black, sporadic PTC; red,
post-Chernobyl PTC. Each row represents a cDNA clone and each column
a tumour RNA sample. Red indicates upregulation, green downregulation,
and black no change. The normalisation and clustering procedures are

















































Figure 2 Samples were collapsed from the 2400 dimensions gene
expression space into two dimensions using multidimensional scaling, a
mathematical transformation that preserves intersample distance relation-
ship. The distance metrics used here is Pearson correlation. Autonomous
adenomas are in italic, sporadic PTC in bold and post-Chernobyl PTC in
standard characters. The intersample distances in the two-dimensional
embedding are expressed in arbitrary units, but are proportional on
average to the gene space correlation distances (not shown).
Post-Chernobyl and sporadic PTC have the same phenotype
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ssound alternative to the ad hoc two-fold change threshold used in
many publications to declare a gene differentially expressed, SAM
uses the false discovery rate (FDR), that is, an estimate of the
probability that the genes found to be differentially expressed are
false positives. When comparing adenoma and PTC, SAM
detected 168 differentially expressed genes in 2400 at an FDR of
1%. When comparing sporadic and chPTC, no differentially
expressed genes could be found even using a less stringent
FDR of 5%.
Supervised classification fails to find a signature
separating sporadic and chPTC
None of the genes detected by SAM could perfectly separate
adenomas from PTC when considered alone. Hence, we searched a
set of genes leading to a more accurate adenoma/PTC separation
when considered collectively. The classification method proposed
by Golub et al (1999) finds genes that show large and consistent
expression differences between two groups of samples (see
Materials and Methods). A set of such genes is called a signature.
We searched for signatures ranging in size from 1 to 1000 genes.
The predictive value of the signatures for classification was
measured for each size through cross-validation (see Materials and
Methods). The best signatures were composed of six genes, and
resulted in a misclassification rate of 7% (Po0.01). These six genes
were also identified by SAM with an FDR o0.001. Smaller
signatures lead to higher error rates. Only the average behaviour of
the genes composing the signature indicates a clear adenoma/PTC
distinction. Neither the procedure of Golub et al (1999), nor Pelora
(Dettling and Bu ¨hlmann, 2004) could find a signature classifying
sporadic and chPTC better than a random class assignation. To
check that we found of a signature separating adenomas from PTC,
but no signature separating sporadic from chPTC, because fewer
samples were used in this latter classification task – adenomas are
excluded – we ran the adenoma/PTC classification using sPTC
only. Error rates as low as 3% (Po0.01) were obtained with a 36
genes signature.
Cross-platform control on the basis of 6425 genes shows
that sporadic and chPTC expression data sets are as highly
correlated as two independent sPTC data sets
The 2400 randomly selected cDNAs present on the Micromax
slides cover about 8% of the potential human transcriptome. We
therefore wondered whether the similarity between sporadic and
chPTC would hold for a larger number of genes. In addition,
published comparison of different microarray platforms suggests
strong platform-specific effects (Detours et al, 2003), raising the
possibility that our results relying on Micromax arrays may not be
reproducible on other platforms. We addressed these issues by
comparing PTC data generated on different platforms in our
laboratory and in another laboratory, which uses completely
independent protocols to select tumours and to process samples.
The first additional data set was produced in-house as follow: 14
sPTC RNA samples were pooled and hybridised together with a
patient-matched nontumour thyroid tissue pool on Human 5k
dual channels microarrays from the Flanders Interuniversity
Institute for Biotechnology (VIB, Leuven) covering about 16000




















































































Figure 3 Validation of microarray data by real-time RT–PCR analysis of selected genes, in PTC and hyperfunctioning autonomous adenomas samples
(7s.e.m.).
Table 2 Correlations between cDNA and Huang et al oligonucleotide
microarray data (see text for details)
VIB sPTC VIB chPTC VIB AA
Correlations on all 6425 genes
Huang sPTC 0.49 0.64 0.03
Correlations on the 50% most expressed genes
Huang sPTC 0.6 0.74 0.02
Post-Chernobyl and sporadic PTC have the same phenotype
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ssamples using VIB’s Human 21k and Human 5k arrays,
respectively. The second data set relies on completely indepen-
dent technologies and biological material. Huang et al (2001)
hybridised eight PTC and eight patients-matched nontumoral
tissues on Affymetrix (Affx) HGU95 oligonucleotide microarrays.
The Affymetrix probe design is unlikely to share the same
crossreactivity patterns as those of the cDNA platforms we used.
In addition, Huang’s samples were selected and processed in the
United States, independently from ours. After normalisation,
intensity log-ratios were averaged over the eight patients in
order to simulate a pool comparable to our in-house, VIB, pool
data.
Correlations between averaged log-ratios were then computed
over the 6425 genes represented on the HGU95, VIB 5k and VIB
21k platforms. The results are shown in Table 2. Correlations
between patient-averaged Affx PTC data and our three RNA pools
data sets were 0.49 for Affx PTC vs our sPTC, 0.64 for Affx PTC vs
chPTC. Thus, the Affx PTC and chPTC data sets are at least as
correlated as the two independent sPTC data sets. By contrast,
correlation was only 0.03 between the Affx PTC and the adenoma
data sets. This control demonstrates that the high correlation
between the PTC data sets is not a statistical or a technology-
related artifact. The higher correlation with chPTC may be due to
the fact that this pool was hybridised on Human 21k slides, which
are based on a more recent and more accurate technology than
that of the Human 5k slides used for sPTC. Considering only the
50% most expressed genes in the calculation increased the
correlation between the two sPTC data sets and the correlation
between Huang et al data and our chPTC data, but it did not
increase the correlation between the Huang et al data set and our
adenoma data.
DISCUSSION
Our results show that (1) RNA profiles from sporadic and chPTC
do not permit identification of a molecular signature specific for
radiation-induced or sPTC, on the basis of the expression of 2400
randomly selected genes, while AAs and PTC show distinct gene
expression signatures and (2) sporadic and chPTC pools are as
strongly correlated as two independently derived PTC pools on the
basis of 6425 genes. Huang’s (Huang et al, 2001) data rely on
independent tissue samples selected by different pathologists,
processed in an independent laboratory, and hybridised with a
different microarray technology. Thus, artefacts pertaining to these
matters are controlled for.
Cross-platform integration is necessary if the full potential of
high-throughput expression technologies is to be realised
(Detours et al, 2003; Moreau et al, 2003). The similarities between
our dual channel cDNA data and Huang’s single channel
oligonucleotide data contrast with a widely cited paper reporting
that these technologies may not be comparable (Kuo et al, 2002).
According to this report, Affymetrix and cDNA microarrays
measurements of gene expression in NCI 60 cancer cell lines are
poorly correlated. This discrepancy could be due to the fact that
we compare log-ratios with log-ratios while Kuo et al (2002)
compares MAS 4.0 average difference (i.e. expression level
computed by the Affymetrix microarray analysis software) with
either data from a single cDNA channel, or with log-ratios of the
two cDNA channels. In addition, we found that oligonucleotide
and cDNA data were comparable only after appropriate data
normalisation. Using the original normalisation of Huang, based
on the method of Li and Wong (2001) led to weak correlations
with cDNA data (not shown). By contrast, investigation is limited
to MAS 4.0 expression measures in Kuo et al paper and cDNA
data were not normalised.
One caveat of this work is the limited number of genes
investigated in the multiple samples analysis, and the fact that our
second study, extended on more genes, has been performed with
pooled samples. However, we may consider that, when these data
are taken together, the results of these studies are conclusive. In
addition, preliminary results using 16000 genes arrays are in
accordance with the data presented here.
The clinical features of French or Italian sporadic papillary
carcinomas in children were similar to those of children’s post-
Chernobyl carcinomas (Leenhardt and Aurengo, 2000). Similarly,
thyroid cancers in comparably young children in the US who had
been exposed to external head and neck irradiation behaved
clinically as those of nonexposed children (Becker et al, 1996). This
led to the suggestion that radiation-induced thyroid tumours
should be treated in the same way as nonradiation-induced
tumours (Schneider and Fogelfeld, 1997). This similarity between
sporadic and radiation-induced PTC might be explained by the
hypothesis that part or most of the sporadic papillary cancers
encountered in the normal population might be due to natural
background irradiation (DeGroot, 1989). However, the proportion
of such cancers due to the Chernobyl accident in Western
countries is certainly negligible (Malone et al, 1991), and the
possibility of Chernobyl radiation is ruled out for the sPTC from
the US patients considered in this study. The similarity of gene
expression profiles of post-Chernobyl, Western European, and US
PTC validates quantitatively the identification of these tumours by
pathologists on the basis of their qualitative judgment. Although
the post-Chernobyl patients are younger than the sporadic patients
(although five out of 12 are older than 18), and often present
lymph node metastases, the fact that the gene expression patterns
are similar is a further argument suggesting that all these
carcinomas represent the same disease.
Besides clinical similarities, some genetic differences have
been reported between sporadic and chPTC. Whereas RET/
PTC3 rearrangements dominate in post-Chernobyl carcinomas
(Klugbauer et al, 1995; Nikiforov et al, 1997; Thomas et al, 1999;
Santoro et al, 2000), both RAF mutations and RET/PTC1 or RET/
PTC3 rearrangements are predominantly found in adult sporadic
carcinomas. Recent findings revealed that BRAF mutations are
usually rare in childhood thyroid carcinoma, both sporadic and
radiation related, suggesting that thyroid carcinomas involving a
BRAF mutation may have a longer latency period than those
involving gene rearrangements (Kumagai et al, 2004; Lima et al,
2004). BRAF mutations and RET/PTC rearrangements are
mutually exclusive in papillary carcinomas, both activating
constitutively the RET/PTC–RAS–BRAF–MAPK pathway
(Kimura et al, 2003; Soares et al, 2003). Of course, different levels
of activity of this oncogenic pathway could lead to quantitative
differences in growth rates and phenotypic expression. Our results
suggest that genetic differences, RET/PTC-, BRAF-related, or
others, between sporadic and chPTC are not mirrored by gene
expression in the tumours. This supports the view that whatever
the initial event, the phenotype of the tumour results from the
transduction pathway activated, that is, in this case mainly the
MAP kinase cascade, with different levels of activity (De Vita et al,
2000; Melillo et al, 2001). The cohort of post-Chernobyl patients,
for which the timing of the cancer-causing event is precisely
known, is a unique source of information for understanding the
progression of naturally occurring cancers. Our clinical and
therapeutical knowledge of sporadic papillary carcinomas can
therefore be applied to the post-Chernobyl diseases and con-
versely. In particular, the measured delay between initial causing
event and appearance of the disease in the post-Chernobyl patients
provides a clue to estimate the timing of such events in sporadic
carcinomas.
In conclusion, on the basis of their similar pathology, it is
generally assumed that post-Chernobyl thyroid cancers are
identical to sporadic papillary carcinomas. In this work, we
investigated gene expression in both types of cancers by a variety
of microarray methods and our analyses suggest that these gene
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sexpressions cannot be distinguished, although both tumours are
clearly distinct from AAs. Post-Chernobyl, radiation-induced
thyroid cancers and sporadic thyroid papillary carcinomas thus
most likely represent the same disease. It does not exclude the
possibility that further analysis will demonstrate that the post-
Chernobyl carcinomas might belong to a more homogeneous
restricted subset of carcinomas. This could even be expected owing
to their similar induction mechanism, period of initiation and the
similar age of patients of the investigated cohort.
ACKNOWLEDGEMENTS
We thank Chantal Degraef for excellent technical assistance. This
work was supported by the Ministe `re de la Politique Scientifique
(PAI), the Fonds de la Recherche Scientifique Me ´dicale, Te ´le ´vie,
Fe ´de ´ration Belge contre le Cancer, Fondation Wiener-Anspach,
Fondation David et Alice Van Buuren, Fortis Banque Assurances,
UCB-Re ´gion Wallonne. VD is supported by European Union’s
Marie Curie Grant MEIF-CT-2003-501459.
REFERENCES
Becker DV, Robbins J, Beebe GW, Bouville AC, Wachholz BW (1996)
Childhood thyroid cancer following the Chernobyl accident: a status
report. Endocrinol Metab Clin N Am 25: 197–211
Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M,
Suarez HG (1997) High prevalence of activating ret proto-oncogene
rearrangements, in thyroid tumors from patients who had received
external radiation. Oncogene 15: 1263–1273
Cohen J, Xing MZ, Mambo E, Guo ZM, Wu GG, Trink B, Beller U, Westra
WH, Ladenson PW, Sidransky D (2003) BRAF mutation in papillary
thyroid carcinoma. J Natl Cancer Inst 95: 625–627
De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa
A, Billaud M, Fusco A, Tsichlis PN, Santoro M (2000) Tyrosine 1062 of
RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-
activated protein kinase pathways leading to PC12 cell survival. Cancer
Res 60: 3727–3731
DeGroot LJ (1989) Clinical review 2: diagnostic approach and management
of patients exposed to irradiation to the thyroid. J Clin Endocrinol Metab
69: 925–928
Deleu S, Allory Y, Radulescu A, Pirson I, Carrasco N, Corvilain B, Salmon I,
Franc B, Dumont JE, Van Sande J, Maenhaut C (2000) Characterization
of autonomous thyroid adenoma: metabolism, gene expression, and
pathology. Thyroid 10: 131–140
Detours V, Dumont JE, Bersini H, Maenhaut C (2003) Integration and
cross-validation of high-throughput gene expression data: comparing
heterogeneous data sets. Febs Lett 546: 98–102
Dettling M, Bu ¨hlmann P (2004) Finding predictive gene groups from
microarray data. J Multivariate Anal 90: 106–131
Dudoit S, Fridlyand J, Speed TP (2002) Comparison of discrimination
methods for the classification of tumors using gene expression data. JA m
Statist Assoc 97: 77–87
Eszlinger M, Krohn K, Frenzel R, Kropf S, Tonjes A, Paschke R (2004) Gene
expression analysis reveals evidence for inactivation of the TGF-beta
signaling cascade in autonomously functioning thyroid nodules.
Oncogene 23: 795–804
Finley DJ, Arora N, Zhu BX, Gallagher L, Fahey TJ (2004a) Molecular
profiling distinguishes papillary carcinoma from benign thyroid nodules.
J Clin Endocrinol Metab 89: 3214–3223
Finley DJ, Zhu BX, Barden CB, Fahey TJ (2004b) Discrimination of benign
and malignant thyroid nodules by molecular profiling. Ann Surg 240:
425–436
Fugazzola L, Pilotti S, Pinchera A, Vorontsova TV, Mondellini P,
Bongarzone I, Greco A, Astakhova L, Butti MG, Demidchik EP, Pacini
F, Pierotti MA (1995) Oncogenic rearrangements of the Ret proto-
oncogene in pupillary thyroid carcinomas from children exposed to the
Chernobyl nuclear accident. Cancer Res 55: 5617–5620
Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP,
Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES
(1999) Molecular classification of cancer: class discovery and class
prediction by gene expression monitoring. Science 286: 531–537
Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K,
LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, De La Chapelle A
(2001) Gene expression in papillary thyroid carcinoma reveals highly
consistent profiles. Proc Natl Acad Sci USA 98: 15044–15049
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U,
Speed TP (2003) Exploration, normalization, and summaries of high
density oligonucleotide array probe level data. Biostatistics 4: 249–264
Jhiang SM (2000) The RET proto-oncogene in human cancers. Oncogene 19:
5590–5597
Kimura ET, Nikiforova MN, Zhu ZW, Knauf JA, Nikiforov YE, Fagin JA
(2003) High prevalence of BRAF mutations in thyroid cancer: genetic
evidence for constitutive activation of the RET/PTC–RAS–BRAF
signaling pathway in papillary thyroid carcinoma. Cancer Res 63:
1454–1457
Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM (1995) High
prevalence of RET rearrangement in thyroid tumors of children from
Belarus after the Chernobyl reactor accident. Oncogene 11: 2459–2467
Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, Ishikawa
N, Sugino K, Ito K, Jeremiah S, Thomas GA, Bogdanova TI, Tronko MD,
Nagayasu T, Shibata Y, Yamashita S (2004) Low frequency of
BRAFT1796A mutations in childhood thyroid carcinomas. J Clin
Endocrinol Metab 89: 4280–4284
Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS (2002)
Analysis of matched mRNA measurements from two different micro-
array technologies. Bioinformatics 18: 405–412
Leenhardt L, Aurengo A (2000) Post-Chernobyl thyroid carcinoma in
children. Baillieres Best Pract Res Clin Endocrinol Metab 14: 667–677
Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays:
Expression index computation and outlier detection. Proc Natl Acad Sci
USA 98: 31–36
Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro
M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G,
Williams D, Sobrinho-Simoes M (2004) BRAF mutations are not a major
event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol
Metab 89: 4267–4271
Malone J, Unger J, Delange F, Lagasse R, Dumont JE (1991) Thyroid
consequences of Chernobyl accident in the countries of the European
community. J Endocrinol Invest 14: 701–717
Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR,
Schlessinger J, Lax I (2001) Docking protein FRS2 links the protein
tyrosine kinase RET and its oncogenic forms with the mitogen-activated
protein kinase signaling cascade. Mol Cell Biol 21: 4177–4187
Moreau Y, Aerts S, De Moor B, De Strooper B, Dabrowski M (2003)
Comparison and meta-analysis of microarray data: from the bench to the
computer desk. Trends Genet 19: 570–577
Nikiforov YE, Rowland JM, Bove KE, MonforteMunoz H, Fagin JA (1997)
Distinct pattern of ret oncogene rearrangements in morphological
variants of radiation-induced and sporadic thyroid papillary carcinomas
in children. Cancer Res 57: 1690–1694
Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA,
Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov
YE (2004) Low prevalence of BRAF mutations in radiation-induced
thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett
209: 1–6
Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F,
Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov
YE (2003) BRAF mutations in thyroid tumors are restricted to papillary
carcinomas and anaplastic or poorly differentiated carcinomas arising
from papillary carcinomas. J Clin Endocrinol Metab 88: 5399–5404
Pfaffl MW (2001) A new mathematical model for relative quantification in
real-time RT-PCR. Nucleic Acids Res 29: e45
R development Core Team (2004) R: A language and environment for
statistical computing. Vienna, Austria: R Foundation for Statistical
Computing http://www.R-project.org.
Robbins J, Schneider AB (1998) Radioiodine-induced thyroid cancer:
studies in the aftermath of the accident at Chernobyl. Trends Endocrinol
Metab 9: 87–94
Roudebush CP, Asteris GT, DeGroot LJ (1978) Natural history of radiation-
associated thyroid cancer. Arch Intern Med 138: 1631–1634
Santoro M, Thomas GA, Vecchio G, Williams GH, Fusco A, Chiappetta
G, Pozcharskaya V, Bogdanova TI, Demidchik EP, Cherstvoy ED,
Post-Chernobyl and sporadic PTC have the same phenotype
V Detours et al
1551




















sVoscoboinik L, Tronko ND, Carss A, Bunnell H, Tonnachera M, Parma J,
Dumont JE, Keller G, Hofler H, Williams ED (2000) Gene re-
arrangement and Chernobyl related thyroid cancers. Br J Cancer 82:
315–322
Schneider AB, Fogelfeld L (1997) Radiation-induced endocrine tumors.
Cancer Treat Res 89: 141–161
Schwender H (2003) Assessing the false discovery rate in a statistical
analysis of gene expression data Chapter 5. Department of Statistics,
University of Dortmund http://de.geocities.com/holgerschw/thesis.pdf.
Shibata Y, Yamashita S, Masyakin VB, Panasyuk GD, Nagataki S (2001) 15
years after Chernobyl: new evidence of thyroid cancer. Lancet 358:
1965–1966
Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V,
Botelho T, Seruca R, Sobrinho-Simoes M (2003) BRAF mutations and
RET/PTC rearrangements are alternative events in the etiopathogenesis
of PTC. Oncogene 22: 4578–4580
Tallini G, Asa SL (2001) RET oncogene activation in papillary thyroid
carcinoma. Adv Anat Pathol 8: 345–354
Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy
ED, Tronko ND, Bogdanova TI, Chiappetta G, Viglietto G, Pentimalli F,
Salvatore G, Fusco A, Santoro M, Vecchio G (1999) High prevalence of
RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl
thyroid papillary carcinomas: a strong correlation between RET/PTC3
and the solid-follicular variant. J Clin Endocrinol Metab 84: 4232–4238
Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:
5116–5121
Venables WN, Ripley BD (2002) Modern applied statistics with S Fourth
edn, Berlin: Springer
Venet D (2003) MatArray: a Matlab toolbox for microarray data.
Bioinformatics 19: 659–660
Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H
(2003) Hepatocyte growth factor receptor, matrix metalloproteinase-11,
tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated
in papillary thyroid carcinoma: a cDNA and tissue microarray study.
Clin Cancer Res 9: 68–75
Post-Chernobyl and sporadic PTC have the same phenotype
V Detours et al
1552
British Journal of Cancer (2005) 92(8), 1545–1552 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s